Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Blueprint Medicines Corporation    BPMC

BLUEPRINT MEDICINES CORPORATION

(BPMC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Blueprint Medicines Says FDA Approves Gavreto to Treat Thyroid Cancer

12/01/2020 | 03:58pm EST

By Stephen Nakrosis

Blueprint Medicines Corp. on Tuesday said the U.S. Food and Drug Administration approved Gavreto as a treatment for certain types of thyroid cancer.

The company said the FDA approved Gavreto, or pralsetinib, as a treatment for patients with RET-altered thyroid cancers.

Blueprint Medicines said it is co-commercializing Gavreto in the U.S. with Genentech, under Blueprint's collaboration with Roche.

"In the Phase 1/2 ARROW trial, Gavreto showed durable efficacy and was generally well-tolerated in patients with RET-altered thyroid cancers with or without prior systemic therapy," Blueprint said.

"Earlier this year, the FDA granted accelerated approval to Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer as detected by an FDA approved test," the company added.

At 3:36 p.m. EST, Blueprint Medicines' shares were trading 2.5% lower on the Nasdaq at $105.83. Year to date, the stock is up over 31%.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

12-01-20 1557ET

Stocks mentioned in the article
ChangeLast1st jan.
BLUEPRINT MEDICINES CORPORATION 1.52% 102.9 Delayed Quote.-9.62%
NASDAQ COMP. 0.69% 13635.991758 Delayed Quote.5.08%
ROCHE HOLDING AG 0.74% 320.8 Delayed Quote.3.06%
All news about BLUEPRINT MEDICINES CORPORATION
01/12BLUEPRINT MEDICINES : SVB Leerink Adjusts Blueprint Medicines' Price Target to $..
MT
01/11BLUEPRINT MEDICINES : Names New Chief Medical Officer
MT
01/11BLUEPRINT MEDICINES CORP : Entry into a Material Definitive Agreement, Change in..
AQ
01/11BLUEPRINT MEDICINES : Announces R&D Leadership Transitions
PR
01/11BLUEPRINT MEDICINES : Reports Portfolio Milestones and Outlines 2021 Roadmap for..
PR
01/05BLUEPRINT MEDICINES : Announces Inducement Grants Under NASDAQ Listing Rule 5635..
PR
2020BLUEPRINT MEDICINES : JMP Securities Adjusts Blueprint Medicines PT to $152 From..
MT
2020BLUEPRINT MEDICINES CORP : Other Events, Financial Statements and Exhibits (form..
AQ
2020BLUEPRINT MEDICINES : Submits Supplemental New Drug Application to FDA for Ayvak..
MT
2020BLUEPRINT MEDICINES : Submits Supplemental New Drug Application to FDA for AYVAK..
PR
More news
Financials (USD)
Sales 2020 789 M - -
Net income 2020 311 M - -
Net cash 2020 301 M - -
P/E ratio 2020 18,8x
Yield 2020 -
Capitalization 5 735 M 5 735 M -
EV / Sales 2020 6,89x
EV / Sales 2021 31,6x
Nbr of Employees 420
Free-Float 98,0%
Chart BLUEPRINT MEDICINES CORPORATION
Duration : Period :
Blueprint Medicines Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEPRINT MEDICINES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 119,69 $
Last Close Price 102,90 $
Spread / Highest target 47,7%
Spread / Average Target 16,3%
Spread / Lowest Target -21,3%
EPS Revisions
Managers and Directors
NameTitle
Jeffrey W. Albers President, Chief Executive Officer & Director
Daniel S. Lynch Executive Chairman
Kathryn Haviland Chief Operating Officer
Michael Landsittel Chief Financial Officer
Marion Dorsch Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEPRINT MEDICINES CORPORATION-9.62%5 649
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-10.58%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059